These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29576815)

  • 1. Modification of Initial Highly Active Antiretroviral Therapy (HAART) Regimen in Paediatric HIV Patients.
    Low YS; Islahudin F; Razali KAM; Adnan S
    Open AIDS J; 2018; 12():11-19. PubMed ID: 29576815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors.
    Kiguba R; Byakika-Tusiime J; Karamagi C; Ssali F; Mugyenyi P; Katabira E
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):218-23. PubMed ID: 17438478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection.
    Mocroft A; Phillips AN; Soriano V; Rockstroh J; Blaxhult A; Katlama C; Boron-Kaczmarska A; Viksna L; Kirk O; Lundgren JD;
    AIDS Res Hum Retroviruses; 2005 Sep; 21(9):743-52. PubMed ID: 16218797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
    Cicconi P; Cozzi-Lepri A; Castagna A; Trecarichi EM; Antinori A; Gatti F; Cassola G; Sighinolfi L; Castelli P; d'Arminio Monforte A;
    HIV Med; 2010 Feb; 11(2):104-13. PubMed ID: 19732176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early modification of initial HAART regimen associated with poor clinical outcome in HIV patients.
    Park WB; Choe PG; Kim SH; Jo JH; Bang JH; Kim HB; Kim NJ; Oh MD; Choe KW
    AIDS Res Hum Retroviruses; 2007 Jun; 23(6):794-800. PubMed ID: 17604542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of hepatitis C coinfection on discontinuation and modification of initial HAART in primary HIV care.
    Hooshyar D; Napravnik S; Miller WC; Eron JJ
    AIDS; 2006 Feb; 20(4):575-83. PubMed ID: 16470122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
    Birlie B; Braekers R; Awoke T; Kasim A; Shkedy Z
    BMC Infect Dis; 2017 Jun; 17(1):453. PubMed ID: 28655306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.
    d'Arminio Monforte A; Lepri AC; Rezza G; Pezzotti P; Antinori A; Phillips AN; Angarano G; Colangeli V; De Luca A; Ippolito G; Caggese L; Soscia F; Filice G; Gritti F; Narciso P; Tirelli U; Moroni M
    AIDS; 2000 Mar; 14(5):499-507. PubMed ID: 10780712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-label use of combined antiretroviral therapy, analysis of data collected by the Italian Register for HIV-1 infection in paediatrics in a large cohort of children.
    Chiappini E; Lisi C; Giacomet V; Erba P; Bernardi S; Zangari P; Di Biagio A; Taramasso L; Giaquinto C; Rampon O; Gabiano C; Garazzino S; Tagliabue C; Esposito S; Bruzzese E; Badolato R; Zanaboni D; Cellini M; Dedoni M; Mazza A; Pession A; Giannini AM; Salvini F; Dodi I; Carloni I; Cazzato S; Tovo PA; de Martino M; Galli L;
    BMC Infect Dis; 2022 Jan; 22(1):55. PubMed ID: 35033018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnitude and predictors of first-line antiretroviral therapy regimen change among HIV infected adults: A retrospective cross sectional study.
    Alema NM; Asgedom SW; Maru M; Berihun B; Gebrehiwet T; Atey TM; Demsie DG; Bantie AT; Yehualaw A; Taferre C; Seid SA; Girma T; Allene MD; Tamru SM
    Ann Med Surg (Lond); 2022 Sep; 81():104303. PubMed ID: 36147157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Reason for Regimen Change Among HIV/AIDS Patients Initiated on First Line Highly Active Antiretroviral Therapy in Southern Ethiopia.
    Woldemedhin B; Wabe NT
    N Am J Med Sci; 2012 Jan; 4(1):19-23. PubMed ID: 22393543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of highly active antiretroviral therapy duration in HIV-1-infected children and adolescents in Madrid, Spain, from 1996 to 2012.
    Palladino C; Briz V; Bellón JM; Climent FJ; de Ory SJ; Mellado MJ; Navarro ML; Ramos JT; Taveira N; de José MI; Muñoz-Fernández MÁ;
    PLoS One; 2014; 9(5):e96307. PubMed ID: 24788034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the efficacy and safety of changes in antiretroviral regimens for HIV-infected patients.
    Tanaka H; Wada T; Takayama Y; Matsumoto K; Atsuda K; Satoh M
    J Pharm Pharm Sci; 2014; 17(3):316-23. PubMed ID: 25224346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to initial highly active antiretroviral therapy discontinuation and its predictors among HIV patients in Felege Hiwot comprehensive specialized hospital: a retrospective cohort study.
    Amera TG; Bogale KA; Tefera YM
    AIDS Res Ther; 2021 Dec; 18(1):93. PubMed ID: 34863200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
    Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
    BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection.
    Mocroft A; Phillips AN; Soriano V; Rockstroh J; Blaxhult A; Katlama C; Boron-Kaczmarska A; Viksna L; Kirk O; Lundgren JD;
    AIDS Res Hum Retroviruses; 2005 Jun; 21(6):527-36. PubMed ID: 15989457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increases in duration of first highly active antiretroviral therapy over time (1996-2009) and associated factors in the Multicenter AIDS Cohort Study.
    Slama L; Li X; Brown T; Jacobson LP; Pialoux G; Macatangay B; Bolan RK; Phair J; Palella FJ;
    J Acquir Immune Defic Syndr; 2014 Jan; 65(1):57-64. PubMed ID: 24419062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection.
    Sabundayo BP; McArthur JH; Langan SJ; Gallant JE; Margolick JB
    Pharmacotherapy; 2006 May; 26(5):674-81. PubMed ID: 16637796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.